$9.05
+1.7%ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.
Strong working capital position provides significant operational flexibility and financial cushion.
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.
SPRY • NASDAQ
| ARS Pharmaceuticals, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
41.3M | 50.8M | 71M | 210.5M | 60.1M | 24.5M | 10M | 20.2M | |
203.7M | 263.2M | 157.4M | 63.9M | 0.0 | 0.0 | 0.0 | 0.0 | |
245M | 314M | 228.4M | 274.4M | 60.1M | 24.5M | 10M | 20.2M | |
25.3M | 9.2M | 795K | 0.0 | 1K | 384K | 0.0 | 0.0 | |
25.3M | 8.2M | 0.0 | 0.0 | 0.0 | 380K | 0.0 | 0.0 | |
0.0 | 987K | 795K | 0.0 | 1K | 4K | 0.0 | 0.0 | |
8.4M | 5.2M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 4.7M | 2.4M | 2.3M | 666K | 1.5M | 0.0 | 0.0 | |
6.2M | 1.2M | 0.0 | 1M | 0.0 | 0.0 | 552K | 618K | |
284.9M | 334.3M | 231.6M | 277.7M | 60.7M | 26.4M | 10.5M | 20.8M | |
NON-CURRENT ASSETS | ||||||||
2.5M | 1.1M | 824K | 774K | 693K | 23K | 4.6M | 6M | |
14.5M | 7.7M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
14.5M | 7.7M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 550K | 750K | |
25.8M | 8.1M | 801K | 3M | 23K | 2K | 0.0 | 0.0 | |
42.8M | 16.9M | 1.6M | 3.7M | 716K | 25K | 5.1M | 6.8M | |
327.7M | 351.2M | 233.2M | 281.4M | 61.4M | 26.4M | 15.6M | 27.5M | |
LIABILITIES | ||||||||
CURRENT LIABILITIES | ||||||||
5.7M | 9.9M | 763K | 1.7M | 1.8M | 1.3M | 3.5M | 775K | |
5.7M | 9.9M | 759K | 1.7M | 1.8M | 1.2M | 3.5M | 775K | |
0.0 | 0.0 | 4K | 0.0 | 22K | 75K | 0.0 | 0.0 | |
0.0 | 10.7M | 315K | 2.1M | 639K | 840K | 0.0 | 0.0 | |
588K | 0.0 | 237K | 0.0 | 3.5M | 2.6M | 12.3M | 3.5M | |
0.0 | 42K | 0.0 | 230K | 144K | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 4K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 557K | 0.0 | 0.0 | 1.5M | 3.5M | 0.0 | 0.0 | |
32.8M | 2.3M | 1.1M | 1.5M | 660K | 0.0 | 2.1M | 841K | |
39.1M | 23.4M | 2.4M | 5.4M | 8.2M | 8.2M | 17.9M | 5.1M | |
NON-CURRENT LIABILITIES | ||||||||
96.4M | 0.0 | 0.0 | 0.0 | 4.9M | 7.5M | 0.0 | 0.0 | |
1.1M | 1.5M | 0.0 | 0.0 | 3M | 3.4M | 0.0 | 0.0 | |
76.7M | 69.4M | 0.0 | 2.9M | 76.1M | 21.3M | 0.0 | 0.0 | |
174.2M | 70.9M | 37K | 3.1M | 84.5M | 32.2M | 3.3M | 4.2M | |
0.0 | 42K | 37K | 481K | 624K | 0.0 | 3.3M | 4.2M | |
213.4M | 94.4M | 2.4M | 8.5M | 92.7M | 40.5M | 21.3M | 9.4M | |
SHAREHOLDERS' EQUITY | ||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 53.2M | 53.2M | |
10K | 10K | 10K | 9K | 3K | 223K | 0.0 | 0.0 | |
408.7M | 379.9M | 362M | 349.4M | 11M | 7.7M | 0.0 | 0.0 | |
-294.6M | -123.3M | -131.3M | -76.9M | -42.3M | -22M | -63.8M | -39.8M | |
125K | 220K | 49K | 407K | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 1.0 | 0.0 | 0.0 | 5M | 4.8M | |
114.3M | 256.8M | 230.8M | 272.9M | -31.3M | -14.1M | -5.6M | 18.2M | |
114.3M | 256.8M | 230.8M | 272.9M | -31.3M | -14.1M | -5.6M | 18.2M | |
SUMMARY | ||||||||
327.7M | 351.2M | 233.2M | 281.4M | 61.4M | 26.4M | 15.6M | 27.5M | |
203.7M | 263.2M | 157.4M | 63.9M | 0.0 | 0.0 | 550K | 750K | |
97M | 42K | 274K | 481K | 9M | 10M | 15.6M | 7.7M | |
55.6M | -50.8M | -70.7M | -210M | -51M | -14.5M | 5.6M | -12.4M | |
98,192,572 | 98,192,572 | 98,192,572 | 98,192,572 | 98,192,572 | 98,192,572 | 98,192,572 | 98,192,572 |
SPRY - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 15, 2026 | May 15, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 15, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 12, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 24, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 09, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 09, 2026 | March 09, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 10, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 10, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 29, 2025 | September 29, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 28, 2025 | August 13, 2025 | 2025 |
Continue your SPRY research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.